NCT04480307 - Clinical Trial Assessing Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 17, 2020

Primary Completion Date

January 24, 2022

Study Completion Date

January 24, 2022

Conditions

Multiple Sclerosis

Interventions

DRUG

temelimab 18 mg/kg

temelimab 18 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).

DRUG

temelimab 36 mg/kg

temelimab 36 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).

DRUG

temelimab 54 mg/kg

temelimab 54 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).

DRUG

Placebo

Placebo will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).

Trial Locations (1)

Center for Neurology, Academic Specialist Center, Stockholm